Eldad Melamed

This inventor holds 24 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in CNS Disease Treatment. Top assignees: Tel Aviv University, Brainstorm Cell Therapeutics Ltd., Teva Pharmaceutical Industries Limited. Active years: 1994-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eldad Melamed. Retrieved from https://idiyas.com/inventor/eldad-melamed

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 4)

% Patents Active = 91.7

CIPO Patents = 1

EPO Patents = 8 (Patent Applications = 1)

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 218(Granted Patents)

Location History:

Mevasserett Zion, IL (1994 - 1998)
69341 Tel Aviv, IL (2002)
Or-Yehuda, IL (2007)
Raanana, IL (2012)
Tel Aviv, IL (1999 - 2021)

Company Filing History:

Brainstorm Cell Therapeutics Ltd.

patents

4 out of 505

Teva Pharmaceutical Industries Limited

patents

4. 4 out of 915

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

5. 2 out of 1,168

Yeda Research and Develpment & Co. Ltd

patents

6. 1 out of 1

Brainstorm Ceil Therapeutics Ltd.

11. 3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1994-2021

Loading Chart...

Areas of Expertise:

Mesenchymal Stem Cells

CNS Diseases

Neurotrophic Factors

Stem Cell Therapy

Peptides

Oxidative Stress

Dyskinesias

Parkinson's Disease

Antioxidant Compounds

Ischemic Brain Injury

Pharmaceutical Composition

L-DOPA

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11185572 - Mesenchymal stem cells for the treatment of CNS diseases (2021-11-30),

2. 10869899 - Isolated cells and populations comprising same for the treatment of CNS diseases (2020-12-22),

3. 10744162 - Genetically modified muscle cells which express neurotrophic factors (2020-08-18),

4. 10052363 - Mesenchymal stem cells for the treatment of CNS diseases (2018-08-21),

5. 9879225 - Isolated cells and populations comprising same for the treatment of CNS diseases (2018-01-30),

6. 9717761 - Stem cell-derived neural cells for cell therapy in neurological disorders (2017-08-01),

7. 9474787 - Mesenchymal stem cells for the treatment of CNS diseases (2016-10-25),

8. 9365828 - Genetically modified muscle cells which express neurotrophic factors (2016-06-14),

9. 9023800 - Peptides for the treatment of oxidative stress related disorders (2015-05-05),

10. 8900574 - Mesenchymal stem cells for the treatment of CNS diseases (2014-12-02),

11. 8663987 - Mesenchymal stem cells for the treatment of CNS diseases (2014-03-04),

12. 8647874 - Isolated cells and populations comprising same for the treatment of CNS diseases (2014-02-11),

13. 8378070 - Peptides for the regulation of neurotransmitter sequestration and release (2013-02-19),

14. 8213502 - Method and system for real-time adaptive quantization control (2012-07-03),

15. 8212001 - Peptides for the treatment of oxidative stress related disorders (2012-07-03),

Title: Innovations of Eldad Melamed in the Field of CNS Diseases

Introduction

Eldad Melamed, based in Tel Aviv, IL, is a prominent inventor with a significant contribution to the field of medical innovations, particularly in the realm of central nervous system (CNS) diseases. With a robust portfolio of 22 patents, Melamed has made strides in harnessing stem cell technology to address challenging neurological conditions.

Latest Patents

Among his recent advancements, Melamed's patents include groundbreaking work on mesenchymal stem cells for the treatment of CNS diseases. One of his notable inventions discloses an isolated human cell that comprises at least one mesenchymal stem cell phenotype, which secretes brain-derived neurotrophic factor (BDNF) at a level significantly greater than the basal secretion in traditional mesenchymal stem cells. Additionally, he has developed methods for generating these cells, alongside isolated cell populations that include at least one astrocytic phenotype and one mesenchymal stem cell phenotype, both vital for innovative therapeutic applications.

Career Highlights

Eldad Melamed has collaborated with esteemed organizations throughout his career, notably Ramot at Tel Aviv University Ltd. and Teva Pharmaceutical Industries Limited. His work in these institutions underscores his dedication to leveraging scientific research for the development of therapeutic options in treating CNS diseases.

Collaborations

Throughout his career, Melamed has partnered with esteemed colleagues such as Daniel Offen and Merav Bahat-Stromza. These collaborations highlight the interdisciplinary nature of his research, which combines insights from various scientific backgrounds to propel innovations in stem cell therapy.

Conclusion

Eldad Melamed's innovative approach to utilizing mesenchymal stem cells presents promising avenues for the treatment of CNS disorders. With an impressive array of patents and collaborations that bridge academia and industry, he continues to push the boundaries of medical science, offering hope for patients battling neurological challenges.

Profile summary based on public USPTO records.